Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study

Authors: Jiawei Chen, Xinhai Cui, Hai Zhou, Chao Qin, Qiang Cao, Xiaobing Ju, Pu Li, Hongzhou Cai, Jian Zhu, Xiaoxin Meng, Meilin Wang, Zhengdong Zhang, Pengfei Shao, Jie Li, Changjun Yin

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer and is considered as a new therapeutic target. We suppose that genetic variant rs9904341 in the 5′ UTR region of survivin gene may be associated with the development and progression of prostate cancer (PCa) in Chinese population.

Methods

TaqMan assay method was used to genotype the polymorphism in the hospital-based case–control analysis of 665 patients with PCa and 710 age-matched cancer-free controls. The genetic associations with the occurrence and progression of PCa were calculated by logistic regression.

Results

Our results indicated that compared with GG genotypes, there was a statistically significant increased risk of PCa associated with those with CC genotypes [odds ratios (ORs) = 1.57, 95%confidence intervals (CIs) = 1.17-2.13, P = 0.004]. Moreover, stratification analysis revealed that the association was more pronounced in subgroups of nondrinkers, nonsmokers and those without a family history of cancer (all P < 0.05). In addition, we observed that PSA ≥ 20 was more frequent in patients carrying GC/CC genotypes than in those with a wild type genotype.

Conclusion

The functional survivin rs9904341 genetic variant may have a substantial influence on the PCa susceptibility and evolution.
Literature
1.
Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 1995, 267 (5203): 1456-1462. 10.1126/science.7878464.CrossRefPubMed
2.
3.
4.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3 (8): 917-921. 10.1038/nm0897-917.CrossRefPubMed
5.
6.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396 (6711): 580-584. 10.1038/25141.CrossRefPubMed
7.
Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001, 7 (12): 542-547. 10.1016/S1471-4914(01)02243-2.CrossRefPubMed
8.
Salvesen GS, Duckett CS: IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2002, 3 (6): 401-410. 10.1038/nrm830.CrossRefPubMed
9.
Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004, 64 (20): 7183-7190. 10.1158/0008-5472.CAN-04-1918.CrossRefPubMed
10.
Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC: The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997, 16 (23): 6914-6925. 10.1093/emboj/16.23.6914.CrossRefPubMedPubMedCentral
11.
Li F, Altieri DC: The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999, 59 (13): 3143-3151.PubMed
12.
Leung CG, Xu Y, Mularski B, Liu H, Gurbuxani S, Crispino JD: Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med. 2007, 204 (7): 1603-1611.CrossRefPubMedPubMedCentral
13.
Jiang Y, de Bruin A, Caldas H, Fangusaro J, Hayes J, Conway EM, Robinson ML, Altura RA: Essential role for survivin in early brain development. J Neurosci. 2005, 25 (30): 6962-6970. 10.1523/JNEUROSCI.1446-05.2005.CrossRefPubMed
14.
Xing Z, Conway EM, Kang C, Winoto A: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004, 199 (1): 69-80.CrossRefPubMedPubMedCentral
15.
Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, et al: Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004, 199 (3): 399-410. 10.1084/jem.20032092.CrossRefPubMedPubMedCentral
16.
Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008, 8 (1): 61-70. 10.1038/nrc2293.CrossRefPubMed
17.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin. 2010, 60 (5): 277-300. 10.3322/caac.20073.CrossRefPubMed
18.
McCracken M, Olsen M, Chen MS, Jemal A, Thun M, Cokkinides V, Deapen D, Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin. 2007, 57 (4): 190-205. 10.3322/canjclin.57.4.190.CrossRefPubMed
19.
Kanwar RK, Cheung CH, Chang JY, Kanwar JR: Recent advances in anti-survivin treatments for cancer. Curr Med Chem. 2010, 17 (15): 1509-1515. 10.2174/092986710790979935.CrossRefPubMed
20.
Cheung CH, Cheng L, Chang KY, Chen HH, Chang JY: Investigations of survivin: the past, present and future. Front Biosci. 2011, 16: 952-961. 10.2741/3728.CrossRef
21.
Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005, 65 (11): 4881-4887. 10.1158/0008-5472.CAN-04-3028.CrossRefPubMed
22.
Nomura T, Yamasaki M, Nomura Y, Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep. 2005, 14 (4): 993-997.PubMed
23.
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, et al: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001, 95 (2): 92-95. 10.1002/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9.CrossRefPubMed
24.
McEleny KR, Watson RW, Fitzpatrick JM: Defining a role for the inhibitors of apoptosis proteins in prostate cancer. Prostate Cancer Prostatic Dis. 2001, 4 (1): 28-32. 10.1038/sj.pcan.4500502.CrossRefPubMed
25.
Zhang M, Latham DE, Delaney MA, Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005, 24 (15): 2474-2482. 10.1038/sj.onc.1208490.CrossRefPubMed
26.
McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM: Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002, 51 (2): 133-140. 10.1002/pros.10061.CrossRefPubMed
27.
Xing N, Qian J, Bostwick D, Bergstralh E, Young CY: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate. 2001, 48 (1): 7-15. 10.1002/pros.1076.CrossRefPubMed
28.
Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003, 9 (13): 4914-4925.PubMed
29.
Koike H, Morikawa Y, Sekine Y, Matsui H, Shibata Y, Suzuki K: Survivin is associated with cell proliferation and has a role in 1a,25-dihydroxyvitamin D3 induced cell growth inhibition in prostate cancer. J Urol. 2011, 185 (4): 1497-1503. 10.1016/j.juro.2010.12.005.CrossRefPubMed
30.
Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H: Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 2004, 171 (5): 1855-1860. 10.1097/01.ju.0000120317.88372.03.CrossRefPubMed
31.
Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004, 100 (4): 751-757. 10.1002/cncr.20039.CrossRefPubMed
32.
Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, et al: Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys. 2010, 78 (4): 1095-1103. 10.1016/j.ijrobp.2009.09.007.CrossRefPubMedPubMedCentral
33.
Ma F, Zhang H, Zhai Y, Huang W, Zhao C, Ou S, Zhou H, Yuan W, Wang Z, Wang H, et al: Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One. 2011, 6 (2): e16748-10.1371/journal.pone.0016748.CrossRefPubMedPubMedCentral
34.
Bayram S, Akkiz H, Bekar A, Akgollu E: The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011, 35 (6): 555-559. 10.1016/j.canep.2011.01.004.CrossRefPubMed
35.
Borges Bdo N, Burbano RR, Harada ML: Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med. 2010, 11 (3): 189-193.CrossRefPubMed
36.
Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, Sato S, Mitobe Y, Narita S, Habuchi T: Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011, 129 (8): 1872-1880. 10.1002/ijc.25850.CrossRefPubMed
37.
Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B: Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol. 2010, 18 (3): 880-887.CrossRefPubMed
38.
Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, Yang K, Bai Y: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009, 135 (10): 1341-1349. 10.1007/s00432-009-0575-7.CrossRefPubMed
39.
Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, Shen CH: Association between survivin gene promoter −31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009, 73 (3): 670-674. 10.1016/j.urology.2008.09.048.CrossRefPubMed
40.
Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N: Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009, 24 (2): 145-150. 10.1007/s00384-008-0601-2.CrossRefPubMed
41.
Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, Dong H, Sun Q, Cong R, Chen G, et al: The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 2009, 54 (5): 1021-1028. 10.1007/s10620-008-0441-5.CrossRefPubMed
42.
Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, Kang YM, Kam S, Kim IS, Jun JE, et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008, 60 (1): 31-39. 10.1016/j.lungcan.2007.09.008.CrossRefPubMed
43.
Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, Veress G: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 2007, 60 (3): 303-306.CrossRefPubMed
44.
Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004, 23 (9): 527-537.CrossRefPubMed
45.
O'Neill AJ, Boran SA, O'Keane C, Coffey RN, Hegarty NJ, Hegarty P, Gaffney EF, Fitzpatrick JM, Watson RW: Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma. Prostate. 2001, 47 (3): 183-188. 10.1002/pros.1061.CrossRefPubMed
46.
Kyprianou N, King ED, Bradbury D, Rhee JG: bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer. 1997, 70 (3): 341-348. 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I.CrossRefPubMed
47.
Pan L, Peng XC, Leng F, Yuan QZ, Shan Y, Yu DD, Li ZY, Chen X, Xiao WJ, Wen Y, et al: Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol. 2010, 137 (1): 19-28.CrossRefPubMed
48.
Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, Mahrampour E, Larijani B, Tavakkoly-Bazzaz J, Amoli MM: Association of Survivin Gene Polymorphism With Endometrial Cancer. Int J Gynecol Cancer. 2012, 22 (1): 35-37. 10.1097/IGC.0b013e318229902c.CrossRefPubMed
49.
Brouillette RM, Martin CK, Correa JB, Davis AB, Han H, Johnson WD, Foil HC, Hymel A, Keller JN: Memory for names test provides a useful confrontational naming task for aging and continuum of dementia. J Alzheimers Dis. 2011, 23 (4): 665-671.PubMedPubMedCentral
50.
Hmeljak J, Erculj N, Dolzan V, Kern I, Cor A: BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients. J Cancer Res Clin Oncol. 2011, 137 (11): 1641-1651. 10.1007/s00432-011-1030-0.CrossRefPubMed
51.
Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H: Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol. 2010, 5 (11): 1748-1754. 10.1097/JTO.0b013e3181f18cb9.CrossRefPubMed
52.
Srivastava K, Srivastava A, Mittal B: Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep. 2011, 39 (2): 1509-1516.CrossRefPubMed
Metadata
Title
Functional promoter -31G/C variant of Survivin gene predict prostate cancer susceptibility among Chinese: a case control study
Authors
Jiawei Chen
Xinhai Cui
Hai Zhou
Chao Qin
Qiang Cao
Xiaobing Ju
Pu Li
Hongzhou Cai
Jian Zhu
Xiaoxin Meng
Meilin Wang
Zhengdong Zhang
Pengfei Shao
Jie Li
Changjun Yin
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-356

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine

Research article

Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

Research article

Quality of life of Bahraini women with breast cancer: a cross sectional study

Research article

Survival of patients with operable breast cancer (Stages I-III) at a Brazilian public hospital - a closer look into cause-specific mortality

Research article

Serum p53 antibody detection in patients with impaired lung function

Research article

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits